BRAF and thyroid gland carcinoma: There are clinical implications, as dabrafenib, a BRAF-mutated tyrosine kinase inhibitor, has been shown to have efficacy in well-differentiated radioactive-iodine-resistant thyroid cancer patients and, in combination with trametinib, has been shown to improve overall survival in anaplastic thyroid cancer [48,49].